View Post

Fractures and the Use of Bisphosphonates in Patients With Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: oncnet.com In an interview with Oncology Learning Network, Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, discussed findings from the SWOG S0307 trial, which looked at the occurrence of fractures in patients with breast cancer receiving high-dose bisphosphonates to prevent metastases. Transcript I’m Dr Julie Gralow. I’m a Professor of Breast Medical Oncology …

View Post

Researchers Report Positive Preliminary Data, Favorable Safety Update for Pelareorep in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Aislinn Antrim, Assistant Editor From: pharmacytimes.com The Safety Committee evaluating Onclytics Biotech Inc’s pelareorep has found no safety concerns after evaluating the first 3 cohorts.1 Early findings from the AWARE-1 trial investigating pelareorep for early-stage breast cancer have found that T cell clonality may support the development of a biomarker for the disease, according to a press release.2 More …

View Post

BRCA1/2-Positive Breast Cancer Patients May Respond to Certain Chemotherapy Regimens, Study Finds

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Researchers have homed in on BRCA1/2 mutations as a potential biomarker predictive of which early-stage breast cancer patients will respond to a neoadjuvant chemotherapy regimen containing epirubicin, paclitaxel, cyclophosphamide (iddEPC). Esther Pohl-Rescigno from University Hospital Cologne in Germany led the study published in JAMA Oncology last week. The secondary analysis was based on the 961-patient …

View Post

Addition of ICIs to Neoadjuvant Chemotherapy in High-Risk Breast Cancer Supported by Results of Phase 3 Trial

In Clinical Studies News by Barbara Jacoby

By: Susan Moench, PhD, PA-C From: cancertherapyadvisor.com The pathologic complete response (pCR) rate was nearly 14% higher for women with high-risk nonmetastatic triple-negative breast cancer (TNBC) treated with a neoadjuvant treatment regimen including chemotherapy plus an immune checkpoint inhibitor (ICI) compared with chemotherapy alone, according to results of a phase 3 study published in the New England Journal of Medicine.1 …

View Post

FDA Approves New Drug for Relapsed/Refractory Multiple Myeloma

In Clinical Studies News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com The US Food and Drug Administration (FDA) today approved isatuximab (Sarclisa, Sanofi) in combination with pomalidomide (Revlimid, Celgene) and dexamethasone for the treatment of adult patients with multiple myeloma who have received two or more prior therapies including lenalidomide and a proteasome inhibitor. Isatuximab is an anti-CD38 monoclonal antibody administered by intravenous (IV) infusion that works …

View Post

FDA Grants Priority Review to Olaparib Plus Bevacizumab as Frontline Maintenance in Ovarian Cancer

In Clinical Studies News by Barbara Jacoby

By: Gina Columbus From: onclive.com The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for the combination of olaparib (Lynparza) and bevacizumab (Avastin) for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response (PR) to first-line platinum-based chemotherapy with bevacizumab.1 The designation is based on results from …

View Post

Combination Therapy Improves Progression-Free Survival in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jessica Skarzynski From: curetoday.com The combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with Gemzar (gemcitabine) may give some patients with metastatic breast cancer a new life-extending treatment option, even if they’ve seen disease progression after previous therapy, according to research findings from Memorial Sloan Kettering (MSK) Cancer Center in New York City. Previous research showed that combining Perjeta and …

View Post

John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma

In Clinical Studies News by Barbara Jacoby

From: PR Newswire Triple-drug regimen shown to be superior to conventional treatment in major multicenter study presented at American Society of Hematology annual meeting  Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory (persistent) multiple myeloma. The study was selected as the …

View Post

FDA Panel Supports Pembrolizumab for High-Risk NMIBC

In Clinical Studies News by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9 to 4 supporting the approval of a new drug application (NDA) for pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to …

View Post

First Orally Administered Paclitaxel Shown to Be More Effective than Intravenous Paclitaxel for Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: pharmacytimes.com According to the results of a phase 3 trial presented at the San Antonio Breast Cancer Symposium, patients with metastatic breast cancer (MBC) who received an oral formulation of the chemotherapy drug palitaxel (Taxol) had a better response and survival and less neuropathy than patients who received intravenous (IV) paclitaxel. Researchers evaluated an oral form of paclitaxel in …